Review

**Albumin-linked prostate-specific antigen-activated thapsigargin- and niclosamide-based molecular grenades targeting the microenvironment in metastatic castration-resistant prostate cancer**

Emmanuel S. Akinboye, W. Nathaniel Brennen, Samuel R. Denmeade, John T. Isaacs*

Department of Oncology, Prostate Cancer Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Received 22 May 2018; accepted 6 September 2018
Available online 28 November 2018

**KEYWORDS**

Albumin-linked prodrug; Maleimide coupled albumin delivery; Thapsigargin; Niclosamide

**Abstract** Localized prostate cancer is curable via annihilation of the entire cancer neighborhood by surgery or local radiation. Unfortunately, once metastatic, no available therapy is curative. The vast majority will die despite aggressive systemic combinational androgen-ablation therapies. Thus, there is an urgent need for effective systemic therapeutics that sterilize the entire microenvironment in metastatic castration-resistant prostate cancer (mCRPC). To accomplish this goal, advantage can be taken of the unique biology of mCRPC cells. Like their normal cell of origin, mCRPCs retain expression of the prostate-specific differentiation protein, prostate-specific antigen (PSA), which they abundantly secrete into their extracellular fluid (ECF). This unique, and essentially universal, secretion of enzymatically active PSA into the ECF by mCRPCs creates an exploitable therapeutic index for activation of systemically delivered highly lipophilic toxins as “molecular grenades” covalently linked to cysteine-34 of human serum albumin (HSA) via a stable maleimide containing PSA cleavable peptide such that PSA-dependent hydrolysis (i.e., “detonation”) releases the grenades restrictively within the ECF of mCRPC. This approach decreases dose-limiting host toxicity while enhancing plasma half-life from minutes to days (i.e., pharmacokinetic effect) and increasing the tissue concentration of the maleimide coupled albumin delivery (MAD) in the ECF at sites of cancer due to the enhanced permeability of albumin at these sites (i.e., enhanced permeability and...

* Corresponding author.
E-mail address: isaacjo@jhmi.edu (J.T. Isaacs).

Peer review under responsibility of Second Military Medical University.

https://doi.org/10.1016/j.ajur.2018.11.004
2214-3882/© 2019 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Donald S. Coffey spent more than 50 years in a quest to conquer cancer, particularly prostate cancer. Along the way, one of the most insightful challenges that Don asked each of the legion of his loyal inspired students, fellows, and faculty colleagues was whether they wanted “to study or cure cancer”. Don realized that this was a loaded question since in order to cure cancer, one needs to be armed with sufficient basic science knowledge about cancer to acquire the “wisdom” needed to identify unique vulnerabilities and thus enable more than a simple empiric approach to the development of novel curative therapies. In addition, Don was a champion for the fact that each organ site-specific cancer presents both unique biological problems and opportunities. This realization led Don to be a strong proponent of organ site-specific basic and translational science. Based upon his inspiration and mentoring, after an initial 2 decades of “studying” prostate cancer to acquire sufficient knowledge, our group has spent the last 2 decades translating this basic science wisdom into novel, rational therapeutic approaches.

2. Problems with metastatic castration-resistant prostate cancer (mCRPC) — Low therapeutic index for standard drugs and tumor heterogeneity

There is an urgent need to develop effective systemic therapeutics for mCRPC patients. Obviously the goal for such therapeutics is to produce death of mCRPC cells without an unacceptable amount of killing or injury to the non-malignant cells in normal host tissues. This is a daunting engineering challenge. Remarkably, modest successes, and even cures, are achieved through the use of non-selective, proliferation-dependent chemotherapeutic poisons in a limited number of cancer types due to their high proliferative rate and low cell death threshold compared to normal tissues [1]. The price for such non-selectivity, however, is dose-limiting host toxicities, particularly myelosuppression, which greatly limits therapeutic efficacy against the more slowly proliferating mCRPC cells. This is particularly relevant since we documented more than 20 years ago that while mCRPC cells have the lowest proliferation rate of any type of human cancer cells (i.e., <5% of these malignant cells are proliferating per day), they are still eventually lethal since their death rate is even lower (i.e., <3% of cells die per day) [2]. Since the cells of multiple vital normal organs (e.g., skin, bone marrow, and gut) have proliferation rates of >20% of cells per day, there is almost no therapeutic index for standard proliferation-dependent cytotoxic chemotherapy drugs for the systemic treatment of mCRPCs. Over the last 2 decades, two rapid autopsy studies, one at Johns Hopkins University [3] and the other at the University of Michigan [4] have confirmed our earlier cell kinetic data. In our study at Hopkins, the median growth fraction in 117 individual mCRPC sites was 3% and the mean was (7 ± 1)% [3]. For the Michigan study, the median growth fraction in 103 individual mCRPC sites was 5% and the mean was (5 ± 5)% [4]. These characteristic cell kinetic limitations have led to a profound re-thinking about therapeutic strategies that can activate the proliferation-independent death of mCRPC cells.

Along these lines, cancer cells often acquire an addiction to specific oncogenic signaling pathways that control both their survival and proliferation. For mCRPC, intracellular signaling by nuclear androgen receptor (AR) is the most validated of such oncogenic addictions [5,6]. Thus, novel approaches to block AR signaling are being developed by many investigators in the field. While this is entirely reasonable, there are limitations to such an approach based upon the heterogeneity of AR expression within metastatic sites in individual mCRPC patients. For example, autopsy studies document that AR expression varies widely across mCRPC samples (n = 265) with only 31% of tumor samples having >50% of the malignant cells expressing AR while 42% have <10% and 20% have <1% of the malignant cells expressing AR [4]. Overall, this translates to a median of only 20% of the mCRPC cells expressing AR with a mean of (28 ± 34)% [4]. These results make the sobering prediction that any treatment which completely inhibits intracellular signaling by nuclear AR will be clinically useful, but probably not curative for the vast majority of mCRPC patients.

3. Rationale for prostate-specific antigen (PSA) targeting of mCRPC

To overcome the curative limitation due to the heterogeneity of AR expression, advantage can be taken of the unique biology of prostate cancer cells. Like their normal cell of origin, prostate cancer cells retain expression of the
prostate-specific differentiation protein, PSA, which they abundantly secrete into their extracellular fluid (ECF) [7]. Autopsy studies document that within 265 samples of metastatic sites from 30 mCRPC patients, none lacked detectable expression of PSA and in half of the samples; at least 50% of the cancer cells express PSA with a median expression of 39% and a mean of (43 ± 35)% [4]. PSA is a 33 kDa single-chain glycoprotein that is synthesized and uniquely secreted in large quantities by prostate epithelial cells (i.e., expression is nearly 3 log orders higher in prostate than any other tissue in the human body) [8]. PSA is a serine protease with chymotrypsin-like substrate specificity that is found in 100 μmol/L concentrations in the seminal plasma where its major proteolytic substrates are the seminal gel-forming proteins, semenogelin I and II [9]. In collaboration with Dr. Hans Lilja, we used the PSA cleavage map for the semenogelins to identify a peptide with the amino acid sequence His-Ser-Ser-Lys-Leu-Gln-...-X (HSSKLQ//X) in which hydrolysis between the carboxyl group of Gln (Q) and the amine of the C-terminal amino acid (i.e., Q//X) is highly restricted to PSA recognition (i.e., PSA >2 logs better hydrolysis rate for this substrate than chymotrypsin or any other known cancer-associated proteases including elastase, matrix metalloproteinase (MMP)-2, MMP-9, urokinase, plasmin, tissue plasminogen activator, thrombin, human kallikrein 1(HK1), human kallikrein 2 (HK2), and fibroblast activation protein (FAP)) [9]. We used this HSSKLQ//X substrate to document that prostate cancer cells secrete extremely large (i.e., 1.6–2.1 μmol/L) amounts of enzymatically active PSA into their ECF [7]. Once in the ECF, PSA eventually enters the blood. However, in the blood, PSA is enzymatically inactivated via covalent binding to the serum protease inhibitors α-1-antichymotrypsin and α-2-macroglobulin, which are present in vast molar (i.e., mmol/L) excess [9]. Importantly, a high level of enzymatically active PSA continues to be secreted into the ECF by prostate cancer cells even in patients with high Gleason grade and/or late-stage mCRPC patients [10]. In fact, it is the continuous increase in the serum level of α-1-antichymotrypsin covalently bound PSA (i.e., “complexed” PSA), which requires enzymatically active PSA, that is used as one of the main markers of clinical progression in such lethal patients [10]. Along these lines, a study from MD Anderson documented that <3% of metastatic patients (i.e., 100 out of 4145) treated for prostate cancer had disease progression without an elevation in complexed PSA in the serum [11].

The essentially universal secretion of enzymatically active PSA into the ECF by mCRPC cells creates an exploitable therapeutic index for activation of a combination of systemically delivered "molecular grenades" designed so that their hydrolysis (i.e., "detonation") releases potent lipophilic toxins (i.e., grenades) restrictively within the ECF of mCRPC sites. The chemical engineering requirements for such a combinational PSA-detonated molecular grenade platform is that the individual toxins must be: 1) highly cell penetrant (i.e., lipophilic) when liberated, 2) a potent (i.e., nmol/L) inhibitor of vital, but complementary, intracellular targets (e.g., endoplasmic reticulum [ER] and mitochondria), whose inhibition induces the proliferation-independent death by all cell types, and 3) capable of peptide bond formation with the C-terminal carboxyl group of Gln (Q) in the HSSKLQ//PSA peptide to form a prodrug (i.e., molecular grenade) that is not toxic until hydrolyzed by PSA. Thus, following systemic dosing, such PSA-detonated molecular grenades circulate throughout the body in an inactive state, but only within sites of mCRPC is there a sufficiently high level of enzymatically active PSA to efficiently "pull the pin" on the grenades releasing the cell penetrant toxins from the peptide. Since this hydrolysis occurs in the ECF, the toxins once liberated rapidly penetrate all cell types in the immediate vicinity due to their lipophilicity and do not re-enter systemic circulation. Thus, if a sufficient level of "detonation" occurs, this will not only kill the mCRPC cells, but sterilize the entire PSA-rich metastatic sites including all of the tumor-infiltrating host cells which are stimulating the lethal cancer growth (i.e., tumor endothelial cells, cancer associated fibroblasts [CAFs] and immunosuppressive mesenchymal stem cells [MSCs], myloid derived suppressor cells [MDSCs], and regulatory T-cells [Tregs]) [12–14]. An additional advantage of such selective extracellular hydrolysis is that only a fraction of the cells within the tumor microenvironment need to express PSA since its continuous enzymatic activity amplifies the level of cell penetrant toxin liberated in the ECF within the metastatic site. This stoichiometric amplification negates the problem of tumor cell heterogeneity by inducing a substantial "bystander effect" in which, like a detonated grenade, all cells within the tumor site including both malignant and infiltrating host supporting cells are killed, including those that do not express PSA. Thus, development of resistance is retarded without simultaneously producing non-selective toxicity within normal tissue sites. In addition, unlike many other therapeutic strategies in which expression of the molecular target is assumed, but not validated individually, clinical use of such PSA detonated molecular grenades is "personalized" based upon the detection of α-1-antichymotrypsin bound PSA target in the patient’s serum, thereby, validating this precision medicine approach.

4. First generation PSA-activated thapsigargin (TG) molecular grenade

As the first example of this innovative molecular grenade strategy, a chemically-modified analog of the naturally occurring sesquiterpene γ-lactone, TG was chosen. TG (Fig. 1A) isolated from the Thapsia garganica plant is highly lipophilic and thus cell permeable [15]. Once inside the cell, TG is a potent inhibitor (IC₅₀ 10 nmol/L) of the ER calcium ATPase (i.e., ATP2A2 a.k.a. SERCA 2b) pumps [16]. Our group initially discovered that sustained exposure of human mCRPC cells to TG induces rapid inhibition of their SERCA pumps, resulting in the depletion of the high (i.e., >500 μmol/L) Ca²⁺ in their ER, inducing both an ER stress response and a “capacitance entrance” of extracellular Ca²⁺ [17]. This leads to an initial increase in the intracellular free Ca²⁺ (Caᵢ) from ~40 to >300 nmol/L within minutes followed by a return to baseline over 9–12 h, which is then followed by a delayed sustained increase in Caᵢ to >1 μmol/L over the next 18–36 h [18]. The combination of ER stress and a sustained elevation of Caᵢ eventually results
within several days in the apoptotic death of mCRPC with a lethal dose which causes 50% cell death (LD50) of <50 nmol/L [17–20]. As part of the death response, TG treatment rapidly depletes AR protein expression in AR-positive mCRPC cells [20]. Importantly, unlike drugs like doxorubicin or taxanes which are much more effective in killing proliferating cells, TG is equally effective in killing both non-proliferating and proliferating cells [20]. Furthermore, TG even kills multidrug resistant cells lacking apoptotic Bak and Bax proteins [21]. Such potent TG-induced killing, however, is not cancer cell specific (i.e., TG kills normal cells equally well) [19]. In particular, TG at <100 nmol/L not only kills human umbilical vascular endothelial cells (HUVECs), but also inhibits sprouting by the surviving cells needed for tumor angiogenesis, as documented using a 3-dimensional HUVEC sprouting assay as we have described previously [22]. Thus, if targeted to sites of mCRPC, TG is an ideal agent to annihilate all the cell types present within the cancer neighborhood (i.e., microenvironment).

To target TG’s cell proliferation-independent toxicity to cancer neighborhoods, our group has collaborated with Dr. Søren Brøgger Christensen, one of the original discoverers of TG [15]. Initially, we used an iterative medicinal chemistry approach in which individual side chains of the TG molecule were selectively modified. We determined that position 8 of TG could be modified without significantly affecting SERCA binding. Based upon a combination of enzyme assays, protein crystallography, and in vitro efficacy, we determined that a primary amine-containing 8-O-(12-aminododecanoyl)-8-O-debutanoyl thapsigargin analog (12ADT) has an optimal-length side chain for inhibitory binding to the SERCA pump (IC50 10 nmol/L) and is only slightly less lipophilic than TG, and thus has a cytotoxic potency only slightly less (LD50 55 ± 12 nmol/L) than TG (LD50 13 ± 3 nmol/L) [20,23,24]. The advantage of 12ADT, however, is that it can be covalently coupled via a peptide bond between its primary amine to the C-terminal carboxylic acid of Q in the HSSKLQ PSA-hydrolysable peptide. Direct coupling, however, resulted in a conjugate that is not hydrolyzed efficiently by PSA [19]. Subsequently, we discovered that 12ADT coupled to the C-terminal of leucine (L) to produce L12ADT (Fig. 1A) is more lipophilic and thus more potent (LD50 14 ± 8 nmol/L) than 12ADT. In addition, when the N-terminus of leucine in L12ADT is coupled to the C-terminus of Q in the PSA peptide, the resulting HSSKLQ//L12ADT peptide conjugate (Fig. 1B) is efficiently hydrolyzed (i.e., kcat/Km ratio of 22) by PSA to liberate L12ADT [19]. Thus, this HSSKLQ//L12ADT peptide conjugate is stable in human plasma and selectively toxic (LD50 74 ± 3 nmol/L) to PSA-producing prostate cancer cells in vitro [19].

Pharmacokinetic/pharmacodynamic (PK/PD) and tumor efficacy analyses of human mCRPC xenografts in nude mice documented that this first-generation peptide conjugation (i.e., molecular grenade) functions to solubilize the lipophilicity of TG to allow aqueous systemic intravenous (IV) delivery of the peptide conjugate, and to decrease its penetration into cells at sites lacking enzymatic PSA, thus limiting host toxicity [19]. In fact, the maximum tolerated dose (MTD) for this first generation peptide conjugation was shifted from <1 μmol/kg for TG to >12 μmol/kg. A single IV dose of 12 μmol/kg resulted in a peak serum concentration of 15 ± 1 μmol/L and a half-life (t1/2) of approximately 3 h. Over 24 h, less than 0.5% of the administered peptide–drug conjugate was observed in plasma in the free (i.e., toxic) L12ADT form. When mice bearing growing human mCRPC xenografts were IV dosed daily for 3 days with 12 μmol/kg, the level of liberated L12ADT in the cancer tissues was 170 ± 58 nmol/L, which is 13 times higher than its in vivo LD50 [19]. A regimen of five daily IV injections with 12 μmol/kg dose every 2 weeks resulted in >75% inhibition of the growth of human mCRPC xenografts in mice over a 40 day period without substantial host toxicity, but had no effect on non-PSA producing human renal carcinoma xenografts [19]. However, the therapeutic index for this first generation compound is narrower than anticipated from the in vitro studies. While multiple daily doses of 12 μmol/kg are tolerated, a single dose of 36 μmol/kg is lethal to mice. Similar non-specific toxicity is observed when this first generation PSA detonated TG molecular grenade was evaluated in a preclinical cynomolgus monkey.

Figure 1 Chemical structures of thapsigargin (TG) and TG prodrg (A) Structures of TG and L12ADT; (B) Structure of Mu-HSSKLQ//L12ADT. The arrow indicates the site of prostate-specific antigen (PSA) hydrolysis.
toxicology screen. These studies also documented unexpected dose-limiting toxicity. We recently discovered the mechanism for this toxicity is due to the inability of the 6 amino acid PSA carrier peptide to sufficiently neutralize the high lipophilicity of TG, which allows non-selective permeation of the non-hydrolyzed grenade into normal cells in noncancerous tissues. This result is consistent with our protein crystallization studies, which documented that once inside a cell, potent (i.e., nmol/L) binding to and thus inhibition of the SERCA pump occurs even if the amino-dodecanoyl side chain in position 8 of TG is coupled to small peptides [25].

5. Rationale for maleimide coupled albumin delivery (MAD) for PSA-activated TG molecular grenade

To overcome the problem with the first generation TG-molecular grenade’s promiscuous cellular uptake, we are taking advantage of the fact that human serum albumin (HSA) has a single reactive free cysteine (cys-34) whose reactivity is so efficient that it has been used to produce albumin-coupled prodrugs for clinical trials [26]. Based upon this realization, a second generation molecular grenade has been designed in which cys-34 of HSA is covalently bound to a “stabilized” maleimide (i.e., 2-fluoro-5-maleimidobenzoate) linker covalently coupled to the N-terminus of the PSA-activated peptide ending in L12ADT, (Fig. 2). As we have reported previously, using 2-fluoro-5-maleimidobenzoate for sulfhydryl coupling to HSA produces a much more stable succinimide thioether linkage than compared to the more commonly used N-alkyl maleimides that produce a succinimide thioether ring linkage which undergoes significant spontaneous cleavage by a retro-Michael reaction under physiologic conditions [27]. When this spontaneous succinimide thioether ring cleavage reaction occurs in vivo, it results in dose-limiting systemic toxicity as the therapeutic agent is spontaneously released to circulate in the blood to form adducts with other sulfhydryl containing species like glutathione, cysteine, etc.; thereby, generating a systemically toxic molecule. In contrast, opening of the succinimide-thioether ring (succinimidyl hydrolysis) to form the succinic acid thioether results in the generation of a stable drug–protein conjugation with a very long half-life of up to 2 years [27].

Using this specific 2-fluoro-5-maleimidobenzoate strategy for production of a “stabilized” MAD-conjugated second generation PSA detonated grenade accomplishes four goals. First, coupling to HSA prevents non-selective cell permeation to minimize side effects (i.e., toxicity) to non-PSA producing host tissues outside of sites of mCRPC. Second, this coupling greatly increases the serum half-life of the second generation grenade from hours to days (pharmacokinetic effect). Third, blood vessels in sites of cancer are much more permeable to albumin than in normal tissues, and thus coupling to albumin enhances the extracellular concentration of the grenade specifically at sites of mCRPC via a tumor site-specific process known as the enhanced permeability and retention (EPR) effect [28]. Fourth, this MAD approach creates a modular platform for the production of a “family” of PSA-detonated molecular grenades attacking different, but complementary, critical intracellular targets.

6. MAD for PSA-activated nicosamide molecular grenade

While this MAD approach for second generation PSA-activated TG molecular grenades should significantly increase its anti-prostate cancer efficacy, it is unknown whether it will be curative when used as monotherapy. What is clear, however, is that this general MAD approach provides a modular platform for the creation of other PSA-detonated molecular grenades to induce proliferation-independent cell death selectively within sites of mCRPC via complementary, but SERCA pump inhibition independent, intracellular targets. As a complementary target, we have focused on the unique vulnerability of mCRPC cells via their dependence upon “parasitic” co-option of nutrients from their supporting tumor stroma. This occurs because despite activation of tumor angiogenesis, the metabolic needs of the cancer cells eventually exceed the nutrient level provided by the tumor blood supply, producing a compromised tumor microenvironment. Under this stress, the infiltrating stroma cells composed of endothelial cells, macrophages, fibroblasts, and adipocytes undergoes autophagy/mitophagy to liberate energy-rich nutrients like fatty acids and metabolic intermediates like glutamine and lactic acid into the tumor ECF [29]. These metabolites are efficiently parasitized from the ECF due to enhanced expression of the specific plasma membrane transports for

**Figure 2** Structure of prostate-specific antigen (PSA) activated prodrug of 8-O-(12-[L-leucinoylamino]dodecanoyl)-8-O-debutanoyltapsigargin analog (L12ADT) with 2-fluoro-5-maleimidobenzoamide covalently coupled to the N-terminal of PSA substrate histidine-serine-serine-lysine-leucine-glutamic acid (HSSKLQ).
For these reasons, $^{[18F]}$-fluorodeoxy glucose (FDG) positron pyruvate, and glutamine/glutamate as substrates $^{[35]}$ oxidation using a combination of free fatty acid, lactate/pyruvate, and glutamine/glutamate as substrates $^{[35-37]}$. For these reasons, $^{[18F]}$-fluorodeoxy glucose (FDG) positron emission tomography (PET) imaging is typically not used in prostate cancer patients due to the frequent presence of FDG-negative metastatic sites. This parasitic nutrient cooption of mCRPC is thus unique compared to other solid malignancies since it is not characteristically driven by a high level of aerobic glycolysis (i.e., lacks the Warburg effect), but instead shunts glucose carbons toward lipogenesis $^{[36]}$. This is also consistent with why prostate cancer cells have a striking increase in the number and pleomorphism of mitochondria $^{[36]}$. These results support the hypothesis that additional PSA-detonated grenades targeted at inhibiting mitochondria function provides a highly rational target based upon mCRPC cells’ unique dependence on “parasitic” nutrient co-option, particularly when combined with ER-targeted PSA-detonated TG grenades. Thus, we are synthesizing a mitochondrial-targeted PSA-detonated grenade based upon the FDA-approved salicylanilide anti-helminthic, niclosamide (Fig. 3A). This lipophilic cell-penetrant compound was originally approved for human use 50 years ago based upon its ability to uncouple oxidative phosphorylation and stimulate ATPase activity in the mitochondria of cestodes (e.g., tapeworms), thus killing these parasites $^{[41]}$. Subsequently, over the last 5 years, niclosamide had been documented to kill mammalian cells, including mCRPC cells, with an LC50 $<$1 μmol/L $^{[41,42]}$. The mechanism for such cell death includes its ability to collapse the outer mitochondrial membrane potential; thereby, uncoupling oxidative phosphorylation $^{[43-45]}$. This uncoupling is due to niclosamide’s high lipophilicity and thus cell penetration, where it enters mitochondria to collapse the proton gradient needed for ATP synthesis $^{[46]}$. This protonophoric effect is dependent upon the pKα of the aromatic hydroxyl group of niclosamide, which at physiologic pH allows cycling between a neutral and anionic form (Fig. 3A). This is critical since it enables delocalization of the negative charge of the anionic form to maintain its lipophilicity to allow it to cross the outer mitochondrial membrane where the proton dissociates, releasing the neutral form which re-crosses the outer mitochondrial membrane; thus collapsing the proton gradient $^{[45,46]}$.

Using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) growth and clonogenic survival assays combined with in situ cell staining, we have confirmed that niclosamide not only kills mCRPC cells (i.e., LD50 is 600 nmol/L for LNCaP, 800 nmol/L for CRW22-Rv1, 750 nmol/L for PC-3, and 500 nmol/L for LAPC4 human prostate cancer lines), but that this toxicity involves loss of the mitochondrial outer membrane potential detected as a decrease in mitochondrial ability to convert JC-1 dye from a green to a red fluorescence $^{[47]}$. The well-established mitochondrial uncoupler, carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), was used for comparison (Fig. 3B). We have also confirmed that when given at 25 mg/kg per day (i.e., 76 μmol/kg per day) for 2 weeks via intraperitoneal injection in 5% Tween-80/5% ethanol/90% phosphate buffered saline (i.e., a non FDA-approved vehicle), niclosamide inhibits the in vivo growth of human mCRPC xenografts in nude mice as reported by Alan Gao’s group (Fig. 3C) $^{[42]}$. This inhibition is due to increased cell death within the site of cancer (Fig. 4).

Niclosamide’s potent killing ability is not restricted to malignant cells, but also occurs in normal cells including endothelial cells (i.e., LD50 for HUVECs is 500 nmol/L). In addition, using a three-dimensional sprouting assay, as we have described previously $^{[22,48]}$, we documented that niclosamide inhibits HUVEC sprouting with an IC50 of 200 nmol/L. This raises the serious issue of the therapeutic index for niclosamide as a cancer drug. In addition, a major problem for the clinical development of niclosamide for

Figure 3  (A) Structure of the anionic vs. neutral form of niclosamide; (B) Loss of mitochondrial outer membrane potential detected as a decrease in JC-1 dye red/green fluorescence ratio; (C) In vivo growth inhibition of the CWR-22 human prostate cancer xenograft in nude mice (n = 10 per group) by niclosamide given at 25 mg/kg per day (i.e., 76 μmol/kg per day) for 2 weeks via intraperitoneal (IP) injection in 5% Tween-80/5% ethanol/90% phosphate buffered saline. FCCP, 4-(trifluoromethoxy)phenylhydrazone.
cancer therapy is its poor aqueous solubility (i.e., 0.23 μg/mL or only 700 nmol/L according to the Merck Index). This is significant as the LD50 value for killing cells is essentially equal to niclosamide’s water solubility. This makes achieving a therapeutic blood level via IV dosing using FDA-approved vehicles very difficult. To overcome this solubility issue, we coupled a glycylproline (GP) dipeptide (compound 1) to the amine of a self-cleaving linker (SCL), and the resulting compound 2 is then coupled to the critical aromatic hydroxyl group of niclosamide (compound 3) via an ether or carbamate linkage to produce compound 4 [GP-SCL-niclosamide], chemically as described in Fig. 5.

Formation of GP-SCL-niclosamide (compound 4) not only solubilizes niclosamide (i.e., >100 μmol/L) but also prevents anion formation of the aromatic hydroxyl group, totally preventing its protonophoric ability, totally preventing its protonophoric killing ability. In addition, the GP dipeptide-SCL-niclosamide is chosen because it is an excellent substrate for C-terminal cleavage between P and the self-cleaving linker by either dipeptidyl peptidase IV (DPPIV) or FAP expressed within the cancer microenvironment on the plasma membrane of prostate cancer cells [49] or tumor-infiltrating CAFs/MSCs, respectively, as we have documented previously [50-52]. Once compound 4 is hydrolyzed, the liberated SCL-coupled compound undergoes spontaneous self-cleavage; as we have documented previously with other SCL coupled compounds [50,53], liberating niclosamide with its aromatic hydroxyl group now is able to ionize and thus function as cell penetrant protonophore (Fig. 6). This is documented by the observation that GP-SCL-niclosamide is so efficiently hydrolyzed by DPPIV that it has an essentially identical LD50 as niclosamide for killing DPPIV expressing mCRPC cells in vitro (600 nmol/L for LNCaP, 800 nmol/L for CRW22-Rv1, and 500 nmol/L for LAPC4 human prostate cancer lines), but no ability to kill normal prostatic basal epithelial cells, which lack DPPIV expression, even at 100 μmol/L.

To further restrict the killing ability of a niclosamide molecular grenade to only sites of mCRPC, we are taking advantage of two additional modifications to compound 4. First, the N-terminal G of compound 4 is being covalently linked to the C-terminal Q in the PSA peptide to produce HSSKLQ//GP-SCL-niclosamide. Since both DPPIV and FAP are endopeptidases and thus require a free N-terminal of G in order to hydrolyze the bond between P and the self cleaving linker, liberation of niclosamide from HSSKLQ//GP-SCL-niclosamide requires sequential dual hydrolysis by PSA then DPPIV/FAP. Second, as with the thapsigargin approach, the N-terminus of the HSSKLQ//GP-SCL-niclosamide is being covalently linked to cyst-34 of HSA via a “stabilized” maleimide (i.e., 2-fluoro-5-maleimidobenzoate) containing linker to produce an HSA-coupled PSA/DPPIV dual-detonated niclosamide grenade (Fig. 7). This is being tested for its systemic anticancer efficacy alone and in combination with the HSA-coupled

![Figure 4](image1.png)  
**Figure 4**  
Histology of the CWR-22 human prostate cancer xenograft in vehical control (A) vs. niclosamide (B) treated hosts.

![Figure 5](image2.png)  
**Figure 5**  
Synthetic scheme for glycylproline (GP) coupling via a self cleaving linkers (SCL) to the aromatic hydroxyl group of niclosamide to produce GP-SCL-niclosamide (i.e., compound 4). SCL, self cleaving linker; a, 2-Ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ), Dichloromethane N,N-dimethylformamide-dichloromethane (DMF-DCM); b, 25% piperidine in DMF; c, Diisopropyl azodicarboxylate (DIAID), triphenylphosphine (PPh3), tetrahydrofuran (THF); d, 20% piperidine/DMF.
PSA-detonated TG grenade when given intravenously in an FDA-approved vehicle (i.e., saline).

7. Conclusion

While Don Coffey consistently championed the need for continuing expansion of basic science discoveries, he always challenged us to translate basic science discoveries into "cures" for prostate cancer. Along these lines, the rationale for several MAD-linked PSA-activated molecular grenades for targeting metastatic CRPC have been presented. Additional approaches developed by our group using PSA to active recombinant bacterial toxins (i.e., topsalysin) and a prostate specific membrane antigen activated TG prodrug (i.e., mipsagargin) have entered clinical testing [23,54]. Similar approaches exploiting the unique enzymatic activity of other tumor-associated proteases such as FAP are being developed [52].

Author contributions

Study concept and design: Emmanuel S. Akinboye and John T. Isaacs.

Data acquisition: Emmanuel S. Akinboye and John T. Isaacs.

Data analysis: Emmanuel S. Akinboye and John T. Isaacs.

Drafting of manuscript: Emmanuel S. Akinboye and John T. Isaacs.

Critical revision of the manuscript: W. Nathaniel Brennen and Samuel R. Denmeade.

Conflicts of interest

The authors declare no conflict of interest.

Acknowledgments

We would like to acknowledge the Prostate Cancer Foundation, Department of Defense Prostate Cancer Research Program (W81XWH-16-1-0410), NIH Prostate SPORE (P50 CA058236), Patrick C. Walsh Prostate Cancer Research Fund, and the Hopkins-Allegheny Health Network Cancer Research Fund. Also we wish to thanks the Cell Imaging Facility, Animal Core Facility, and Tissue Histology Core supported by the SKCCC CCSG (P30 CA006973) for their services and assistance and the Mass Spectrometry and
Proteomics Core facility of the Johns Hopkins School of Medicine.

References

[1] Shackney SE, McCormack GW, Cuchural GJ. Growth rate patterns of solid tumors and their relation to responsiveness to therapy. Ann Intern Med 1978;89:107–21.
[2] Berges RR, Vukanovic J, Epstein JJ, CarMichel M, Cisek L, Johnson DE, et al. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995;1:473–80.
[3] Pinski J, Parikh AG, Bova S, Isaacs JT. Therapeutic implications of enhanced Gr/Gf checkpoint control induced by co-culture of prostate cancer cells with osteoblasts. Cancer Res 2001;6:16372–6.
[4] Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64:9209–16.
[5] Litvinov IV, De Marzo AM, Isaacs JT. Is the Achilles’ heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 2003;88:2972–82.
[6] Vander Griend DJ, D’Antonio J, Gurel B, Antony L, Demarzo AM, Isaacs JT. Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells. Prostate 2010;70:90–9.
[7] Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate 2001;48:1–6.
[8] Cunha AC, Weigle B, Kiessling A, Bachmann M, Rieber EP. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett 2006;236:229.
[9] Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett 2006;236:229.
[10] Vander Griend DJ, Antony L, Demarzo AM, Isaacs JT. Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells. Prostate 2010;70:90–9.
[11] Vander Griend DJ, Antony L, Demarzo AM, Isaacs JT. Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells. Prostate 2010;70:90–9.
[12] Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate 2001;48:1–6.
[13] Cunha AC, Weigle B, Kiessling A, Bachmann M, Rieber EP. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett 2006;236:229.
[14] Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett 2006;236:229.
[15] Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate 2001;48:1–6.

[17] Furuya Y, Lundmo P, Short AD, Gill DL, Isaacs JT. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by Thapsigargin. Cancer Res 1994;54:6167–75.
[18] Tombal B, Denmeade SR, Isaacs JT. Assessment and validation of a microinjection method for kinetic analysis of [Ca2+]i in individual cells undergoing apoptosis. Cell Calcium 1999;25:19–28.
[19] Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, et al. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst 2003;95:990–100.
[20] Vander Griend DJ, Antony L, Dalyrple SL, Xu Y, Christensen SB, Denmeade SR, et al. Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells. Mol Cancer Ther 2009;8:1340–9.
[21] Janssen K, Horn S, Niemann MT, Daniel PT, Schulze-Osthoff K, Fischer U. Inhibition of ER Ca2+ pump forces multidrug-resistant cells deficient in Bak and Bax into necrosis. J Cell Sci 2009;122:4481–91.
[22] Isaacs JT, Antony L, Dalyrple SL, Brennen WN, Gerber S, Hammer H, et al. Tasquinimod is an allosteric modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Res 2014;74:1386–99.
[23] Jakobsen CM, Denmeade SR, Isaacs JT, Gady A, Olsen CE, Christensen SB. Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells. J Med Chem 2001;44:4696–703.
[24] Sohoel H, Jensen AM, Moller JV, Poul Nissen P, Denmeade SR, Isaacs JT, et al. Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cells. Bioorg Med Chem 2006:14:2810–5.
[25] Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalyrple S, Dach I, et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med 2012;4:140ra86.
[26] Kratz F. A clinical update of using albumin as a drug vehicle—a commentary. J Contr Release 2014;190:331–6.
[27] Akinboye ES, Rogers OC, Isaacs JT. 2-fluoro-5-maleimidobenzoic acid-linked albumin drug (MAD) delivery for selective systemic targeting of metastatic prostate cancer. Prostate 2018;78:655–63.
[28] Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target 2007;15:457–64.
[29] Martinez-Outschoorn UE, Pestell RG, Howell A, Tykocinski M, Nagajyothi F, Machado FS, et al. Energy transfer in “parasitic” cancer metabolism. Mitochondria are the powerhouse and Achilles’ heel of tumor cells. Cell Cycle 2011;10:4208–16.
[30] Pintus JH, Lu JP, Bidaisee LA, Lin H, Bryskine I, Gupta RS, et al. Androgen-dependent regulation of medium and long chain fatty acids uptake in prostate cancer. Prostate 2007:1330–8.
[31] Wang Q, Hardle RA, Hoy AJ, van Geldermalsen M, Gao D, Fazli L, et al. Targeting ASC127-mediated glutamine uptake blocks prostate cancer growth and tumor development. J Path 2015;236:278–89.
[32] Sanita P, Capulli M, Tieti A, Galatieto GP, Vicentini C, Chiarugi P, et al. Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression. J Path 2015;236:278–89.
[33] Chandler JD, Williams ED, Slavin JL, Best JD, Rogers S. Expression and localization of GLUT1 and GLUT12 in prostate carcinoma. Cancer 2003;97:2035–42.
[34] Jadvar H. Imaging evaluation of prostate cancer with (18)F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imag 2013;1:s5—10.

[35] Liu Y, Zuckier LS, Ghesani NV. Dominant uptake of fatty acid over glucose by prostate cells: a potential new diagnostic and therapeutic approach. Anticancer Res 2010;30:369—74.

[36] Zadra G, Photopoulou C, Loda M. The fat side of prostate cancer. Biochem Biophys Acta 2013;183:1518—32.

[37] Panov A, Ornybayeva Z. Bioenergetic and antiapoptotic properties of mitochondria from cultured human prostate cancer cell lines PC-3, DU145, and LNCaP. PLoS One 2013;8, e72078.

[38] Mao P, Nakao K, Angrist A. Human prostatic carcinoma: an electron microscopic study. Cancer Res 1966;26:955—73.

[39] Sun X, Liao NK, YU JJ. Prognostic value of a mitochondrial functional score in prostate cancer. J Int Med Res 2012;40:371—6.

[40] Grupp K, Jedrzejewksa K, Tsourlakis MC, Koop C, Wilczak W, Adam M, et al. High mitochondria content is associated with prostate cancer progression. Mol Cancer 2013;12:145.

[41] Li Y, Li PK, Roberts MJ, Arend RC, Samant RS, Buchsbaum DJ. Multi-targeted therapy of cancer by niclosamide: a new application for an old drug. Cancer Lett 2014;349:8—14.

[42] Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, et al. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res 2014;20:3198—210.

[43] Jin Y, Lu Z, Ding K, Li J, Du X, Chen C, et al. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res 2010;70:2516—27.

[44] Park SJ, Shin JH, Kang H, Hwang JJ, Cho DH. Niclosamide induces mitochondria fragmentation and promotes both apoptotic and autophagic cell death. BMB Rep 2011;44:517—22.

[45] Fonseca BD, Diering GH, Bidinosti MA, Dalai K, Alain T, Balgi AD, et al. Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling. J Biol Chem 2012;287:17530—45.

[46] Terada H. Uncouplers of oxidative phosphorylation. Environ Health Perspect 1990;87:213—8.

[47] Reers M, Smiley ST, Mottola-Hartshorn C, Chen A, Lin M, Chen LB. Mitochondrial membrane potential monitored by JC-1 dye. Methods Enzymol 1995;260:406—17.

[48] Brennen WN, Nguyen H, Dalrymple SL, Reppert-Gerber S, Kim J, Isaacs JT, et al. Assessing angiogenic responses induced by primary human prostate stromal cells in a three-dimensional fibrin matrix assay. Oncotarget 2016;7:71298—308.

[49] Wilson MJ, Ruhland AR, Quast BJ, Reddy PK, Ewing SL, Sinha AA. Dipeptidylpeptidase IV activities are elevated in prostate cancers and adjacent benign hyperplastic glands. J Androl 2000;21:220—6.

[50] Akinboye ES, Brennen WN, Rosen MD, Bakare O, Denmeade SR. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV (DPP IV) using a tandem enzymatic activation strategy. Prostate 2016;76:703—14.

[51] Aggarwal S, Brennen WN, Kole TP, Schneider E, Topaloglu O, Yates M, et al. Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. Biochemistry 2008;47:1076—86.

[52] Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade SR. Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. J Natl Cancer Inst 2012;104:1320—34.

[53] Kumar SK, Williams SA, Isaacs JT, Denmeade SR, Khan SR. Modulating paclitaxel bioavailability for targeting prostate cancer. Bioorg Med Chem 2007;15:4973—84.

[54] Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT, Denmeade SR. A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst 2007;99:376—85.